medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Seroprevalence of COVID-19 in HIV Population

Author list

1. Dr Shivdas Rajaram Naik, MBBS, Senior Resident, Infectious Diseases, Department of Medicine, AIIMS, New Delhi, India
2. Dr Swasthi S Kumar, MBBS, Junior Resident, Department of Medicine, AIIMS, New Delhi, India
3. Dr Ankit Mittal, MBBS, Senior Resident, Infectious Diseases, Department of Medicine, AIIMS, New Delhi, India
4. Dr Satish Swain, MBBS, Senior Resident, Infectious Diseases, Department of Medicine, AIIMS, New Delhi, India
5. Dr Sanjay Ranjan MBBS, Senior Medical Officer, ART Centre, Department of Medicine, AIIMS, New Delhi, India
6. Dr Manish Soneja, MD, Additional Professor, Department of Medicine, AIIMS, New Delhi, India
7. Dr Sanjeev Sinha, MD, Professor, Department of Medicine, AIIMS, New Delhi, India
8. Dr Neeraj Nischal, MD, Associate Professor, Department of Medicine, AIIMS, New Delhi, India
9. Dr Pankaj Jorwal, MD, Associate Professor, Department of Medicine, AIIMS, New Delhi, India
10. Dr Pradeep Chaturvedi MD, Professor, Department of Reproductive Biology, AIIMS, New Delhi, India
11. Dr Naveet Wig, MD, Professor, Department of Medicine, AIIMS, New Delhi, India

Keywords: HIV, COVID-19, Seroprevalence, PLHA, SARS-CoV-2

Corresponding author:

Dr Naveet Wig, Professor, Department of Medicine, AIIMS New Delhi, India, 110029

Email ID: naveetwig@gmail.com

Word count: 1661 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background: seroprevalence helps us to estimate the exact prevalence of a disease in a population. More than a year since the identification of the disease, it is still not known the exact burden of the disease in the PLHA group. Seroprevalence data in this subset of the population is scarce in most part of the world, including India. The current study aimed to estimate the seroprevalence of anti-SARS-CoV-2 IgG antibody among people living with HIV/AIDS.

Aim: To determine the seroprevalence of SARS-CoV-2 antibodies in PLHA (People living with HIV/AIDS).

Design: This was an observational prospective cohort study.

Method: This cross-sectional study, conducted at a tertiary care hospital in North India, recruited HIV positive patients following at ART centre of the institute. Anti-SARS-CoV-2 IgG antibody levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum sample by the chemiluminescent immunoassay method.

Results: A total of 164 patients were recruited in the study with mean age (±SD) of 41.2 (±15.4) years and 55% male population. Positive serology against SARS CoV-2 was detected in 14% patients (95% C 9.1-20.3%).

Conclusion: The seroprevalence of COVID-19 disease in PLHA was found to be lower than the general population.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Seroprevalence of COVID-19 in HIV Population

Introduction

Since the beginning of the COVID-19 pandemic, there is a fear that people living with HIV-AIDS (PLHA) are at increased risk of acquiring the disease. Also, they were presumably at risk of running a severe course of illness and have higher mortality. These assumptions were based on the observations made in other immunocompromised states.(1) However, to date, no study has been able to show this association. On the contrary, recent studies have shown that these groups of people have a lower incidence of COVID-19. As per a study done in Spain, the incidence of COVID-19 in PLHA was <1%, which was lower than the incidence in their general population.(2) Their results suggest that the risk for COVID-19 diagnosis is not higher in HIV-positive persons than in the general population and that HIV-positive patients receiving NRTI had a lower chance for COVID-19 and related hospitalisation than other HIV-positive persons. This could be attributed to the broad-spectrum antiviral activity of anti-retroviral drugs. However, a lot remains to be known about the HIV-COVID-19 relationship.

As the patients with COVID-19 are mostly asymptomatic, and developing countries are still unable to reach the desired number of rt-PCR tests for diagnosis, surveillance for active cases becomes difficult. This is further compounded by the low sensitivity of the tests.(3) In such situations, serological tests can often help us estimate the disease's overall prevalence in a specified population.

As per a study conducted by Sharma et al., the adjusted seroprevalence of COVID-19 in Delhi during August, September and October was 28.39%, 24.08%, and 24.71%.(4) Whereas the national seroprevalence, as per the study conducted by Indian Council of Medical Research (ICMR), during May-June was 0.7% and during August-September 2020 was 7%, with higher prevalence in urban areas.(5,6)

We conducted this study to estimate the seroprevalence of COVID-19 amongst PLHA following up at the institutional anti-retroviral therapy (ART) centre in North India.

Methodology

This was an observational prospective cohort study designed to determine the seroprevalence of SARS-CoV-2 antibodies in PLHA. Participants were recruited from ART centre, AIIMS New Delhi, between 1st September 2020 and 30th November 2020.

The Anti-Retroviral Therapy (ART) clinic works under the National AIDS Control Organization (NACO), an initiative of the Ministry of Health and Family Welfare of India's Government. The hospital provides tertiary care to the population of Delhi and the neighbouring States, and most of the patients come from the lower socio-economic strata. The centre provides testing for HIV, counselling (before and after testing), free of cost ART drugs and opportunistic infections (OI) screening and treatment.

Most of the patients are from Delhi NCR region. PLHA visiting the centre, aged between 18 years and above at the time of recruitment, were eligible to participate. Informed consent was obtained prior to the enrolment in the study. Patients presenting with features suggestive of COVID-19 disease; were excluded.

The participants provided information at enrolment relating to age, sex, ART regime, symptoms or self-isolating, and diagnostic testing results such as RT-qPCR testing. Participants were also asked to report any signs and illness episodes since the onset of the pandemic in March. All the participants underwent phlebotomy performed by experienced medical staff. 2 ml Serum was drawn, and the

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

samples were tested for antibodies to SARS-CoV-2using the Abbott Architect i4000SR (Abbott Diagnostics, Chicago, USA) which have been validated for use in adults (7).

The Abbott assay is highly specific for SARS-CoV-2 antibodies, using the manufacturer's suggested cut-offs, with specificities of 1.00 (95% CI 0.98 to 1.00) and sensitivities at 0.94 (95% CI 0.86 to 0.98). The assay is a chemiluminescent immunoassay which detects IgG raised against the nucleocapsid protein of SARS-CoV-2. A signal/cut-off (S/CO) ratio of 1.4 was interpreted as reactive, and a S/CO ratio of less than 1.4 was considered non-reactive. Calibration was performed before initiation of test and positive quality control (QC) S/CO 1.65-8.40 and negative quality control S/ CO < 0.78 were fulfilled before analyses of patient samples. (7)

Study data were collected on a predesigned proforma. Data were collected relating to symptoms but not relating to the time of onset or duration of illness. Primary outcome measures were to look for the presence of IgG antibodies to SARS-CoV-2 in serum. SARS-CoV-2 seropositivity was defined as a positive antibody test using the manufacturer's advised positivity cut-off. The secondary outcome measure was to assess the characteristics of COVID-19 disease in PLHA.

Sample size justification

The study was powered to detect the seroprevalence of SARS-CoV-2 antibodies in PLHA. To achieve this, 163 participants were required (assuming alpha of, 0.05 and beta of 0.2). At the beginning of the study, we expected an incidence of no more than 10% of COVID-19 in HIV population. So considering the Prevalence in general population=20%, alpha error = 0.05, power= 95%, the sample size was calculated to be 163 (8).

Statistical Analysis:

Variables including sex, age, symptomatology, the regime of ART and SARS-CoV-2 antibody prevalence were analysed using descriptive statistics (number and proportion for discrete variables, mean and SD for continuous variables). Variables associated with SARS-CoV-2 positivity were analysed using univariate and multivariable analyses to identify predictors of SARS-CoV-2 seropositivity. Initially, all possible variables were assessed using univariate analysis with Fisher's exact testing of categorical data, and the Mann-Whitney U test for continuous data. A *p*-value of less than 0.05 was considered statistically significant.

Results

This was a cross-sectional study conducted at ART centre of All India Institute of Medical Sciences (AIIMS), New Delhi between 1st September and 30th November 2020. During this period, 164 patients were recruited. 116 (70.1%) patients were males (table 1). The mean age (±SD) of the patients was 38.4 ± 11.5 years. The median CD4+Tcell count was 420.2 (268-543). 3 (1.8%) patients were treatment naïve, 156 (95.1%) were on first-line ART treatment (2 NRTI+ 1 NNRTI) and 5 (3.1%) were on second-line ART treatment (2 NRTI+ 1 PI) (Table 2).

23 (14%) patients were found to be positive for COVID-19 antibody by chemiluminescent immunoassay on the Abbott Architect i4000SR (Abbott Diagnostics, Chicago, USA). 19 (82.6%) were males. This makes the overall prevalence of COVID-19 in HIV population in Delhi NCR region to 14.0% (95%CI 9.1-20.3%). Overall, 16.3% of males and 8.3% of females were positive, the difference was not statistically significant. Seroprevalence of COVID-19 was highest in age of more than 50 years, which was 24%. No statistically significant difference among antibody positivity rate was noted in any age group. The median (IQR) CD4+Tcell count was 335 (275-463.5) and was lower than the COVID-19 antibody-negative group. But the difference was not statistically significant.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19 patients reported at least one symptom that could be suggestive of COVID-19 (in the last how many days or months?). 12 (63.2%) had a fever, 10 (52.6%) had a cough, 11(57.9%) had a sore throat, and 2 (10.5%) patients had myalgia, rash and running nose. Out of these 19, only 8 patients had taken the rt-PCR test for COVID-19, but none were positive whereas 4 of them were found to have antibodies against COVID-19.

Discussion

This was the first study to look at the seroprevalence of COVID-19 in HIV population in India. The seroprevalence of COVID-19 in PLHA in Delhi NCR region was found to be 14%.

The serosurvey studies conducted by the Ministry of Health and Family Welfare in Delhi during June-July, August and October respectively revealed the seroprevalence of COVID-19 in Delhi population to be 23.48%, 28.3% and 25.9%. (9,10) A study conducted by Ray et al. in hospitalised patients revealed the seroprevalence to be 19.8%.(11) When compared to the general population, the present study had a lower seroprevalence in PLHA group. Similar results were seen in a study conducted by Papalini et al. Their study, conducted during the early phase of the pandemic, also had a lower seroprevalence of COVID-19 in PLHA than the general population.(12) This may be attributed to the fact that most of the patients were indoors, avoiding social contact, due to fear of acquiring the disease and may not have actually contacted the disease.(13) Another reason for this could be that these patients might not have generated antibodies against COVID-19 or may not have sustained it after getting infected. This is based on our knowledge of impaired immune response in PLHA.(13,14) The role of a few ART drugs, especially lopinavir-ritonavir, were thought as a potential for the treatment of COVID-19 in the initial days.(15) Subsequent literature found it to have no effect.(16) However, the role of other anti-retroviral drugs or their combination is unknown and unexplored.

Majority of the patients in the study had no or minimal symptoms for COVID-19. Since the symptoms are non-specific, they cannot always be attributed to COVID-19. In South Korea, more than 60% of the PLHA patients were asymptomatic for COVID-19 at the time of diagnosis.(17) We also know that at least 40-45% of patients will remain asymptomatic for COVID-19.(18) Another study by Ray et al. at the institute had revealed that most of the patients (>97%) had minor or no symptoms. This likely suggests that, like the general population, asymptomatic infections are prevalent in the PLHA.

Despite these findings, PLHA should not be considered at a lower risk for acquiring infections or developing severe disease. They should continue to practice physical distancing norms and use appropriate face masks to prevent themselves from acquiring COVID-19 infection.

There were limitations to the study. As it was a single centre-based study, it may not be an accurate representation of this subgroup. There were a smaller number of patients who were naïve or on ART other than TLE (tenofovir, lamivudine, efavirenz) and ZLN (zidovudine, lamivudine, nevirapine) combination. Also, since anti-SARS-CoV-2 antibody levels are known to wane over a few months, some cases might have been inadvertently missed in this cross-sectional study.(19) Also, a possibility of false results, as seen with any other antibody-based test, cannot be ruled out.

Conclusion

The present study indicates the seroprevalence of COVID-19 in PLHA to be lower than the general population. However, the exact reasons for explaining this lower seroprevalence is still not clear. A robust study is required to look into this.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Author contributions

Shivdas Naik, Ankit Mittal, Manish Soneja conceived the idea. Shivdas Naik and Ankit Mittal prepared the first draft. Manish Soneja, Sanjeev Sinha, Neeraj Nischal, Pankaj Jorwal and Naveet Wig helped in review of literature. Shivdas Naik, Swasthi Kumar, Satish Swain, Sanjay Ranjan were involved in sample collection and data acquisition. Pradeep Chaturvedi were involved in sample processing and antibody testing. Shivdas Naik and Manish Soneja were involved in data analysis and interpretation. Manish Soneja, Sanjeev Sinha, Neeraj Nischal, Pankaj Jorwal, Pradeep Chaturvedi and Naveet Wig did the proof reading of the article. All authors reviewed the manuscript.

Conflicts of interest: We declare no conflicts of interest.

Ethical clearance: The study was cleared by the institutional ethics committee of AIIMS, New Delhi (IECPG/439/8/2020)

Acknowledgement: We thank the staff at ART centre, AIIMS New Delhi, for their help and support in the study.

Funding: No external funding.

References

1. Xu Z, Zhang C, Wang F-S. COVID-19 in people with HIV. Lancet HIV. 2020 Aug;7(8):e524–6.

2. del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study. Ann Intern Med. 2020 Oct 6;173(7):536–41.

3. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;m1808.

4. Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, et al. The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study [Internet]. Public and Global Health; 2020 Dec [cited 2020 Dec 24]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.12.13.20248123

5. Murhekar M, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj J, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020;152(1):48.

6. Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021 Jan;S2214109X20305441.

7. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. McAdam AJ, editor. J Clin Microbiol. 2020 May 7;58(8):e00941-20, /jcm/58/8/JCM.00941-20.atom.

8. Rosner B. Fundamentals of biostatistics. 8th edition. Boston, MA: Cengage Learning; 2016. 927 p.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

9. Sero-prevalence study conducted by National Center for Disease Control NCDC, MoHFW, in Delhi, June 2020 [Internet]. [cited 2020 Dec 23]. Available from: pib.gov.in/Pressreleaseshare.aspx?PRID=1640137

10. Seroprevalence almost 50% in Central district in Delhi | Cities News,The Indian Express [Internet]. [cited 2020 Dec 23]. Available from: https://indianexpress.com/article/cities/delhi/seroprevalence-almost-50-in-central-district-in-delhi-7048490/

11. Ray A, Singh K, Chattopadhyay S, Mehdi F, Batra G, Gupta A, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Aug [cited 2020 Dec 23]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.08.22.20179937

12. Papalini C, Paciosi F, Schiaroli E, Pierucci S, Busti C, Bozza S, et al. Seroprevalence of anti SARS-CoV2 antibodies in Umbrian persons living with HIV: SARS-CoV-2 and HIV. Mediterr J Hematol Infect Dis. 2020 Oct 27;12(1):e2020080.

13. Karim F, Gazy I, Cele S, Zungu Y, Krause R, Bernstein M, et al. HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease [Internet]. HIV/AIDS; 2020 Nov [cited 2021 Jan 7]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.11.23.20236828

14. Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boelle P-Y. Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2014 Apr 15;58(8):1130–9.

15. Braus M, Morton B. Art therapy in the time of COVID-19. Psychol Trauma Theory Res Pract Policy. 2020 Aug;12(S1):S267–8.

16. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. 2020 Dec 2;NEJMoa2023184.

17. Jung C-Y, Park H, Kim DW, Choi YJ, Kim SW, Chang TI. Clinical Characteristics of Asymptomatic Patients with COVID-19: A Nationwide Cohort Study in South Korea. Int J Infect Dis. 2020 Oct;99:266–8.

18. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020 Sep 1;173(5):362–7.

19. Choe PG, Kang CK, Suh HJ, Jung J, Song K-H, Bang JH, et al. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. Emerg Infect Dis. 2021 Jan;27(1):327–9.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21259066; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1: Baseline details of the Patients.

	Total (n=164)	Positive (n=23)	Negative (n=141)	P-value
Male	116 (70.7%)	19 (82.6%)	97 (68.8%)	0.22
Age (mean ± SD)	38.4 ± 11.5	40.1 ± 11.7	38.0 ± 11.4	0.42
Current CD4+Tcell count (n=162) (median (IQR))	420.2 (268.5-543.75)	335 (275-463.5)	420 (267.5-546.5)	0.30
CD4+Tcell count				0.37
• Less than 200 cells/mm^3	17 (10.4%)	3 (13.4%)	14 (10%)	
• 200-349 cells/mm^3	54 (32.9%)	11 (47.2%)	43 (30.5%)	
• 350-499 cells/mm^3	38 (23.1%)	4 (17.4%)	34 (24.1%)	
• More than 500 cells/mm^3	53 (32.3%)	5 (21.7%)	48 (34.0%)	

Table 2: ART regime of the patient recruited. T-tenofovir, L-lamivudine, E-efavirenz, N- Nevirapine, Z-zidovudine, A/r- ritonavir boosted atazanavir. NRTI- nucleos(t)ide reverse transcriptase inhibitor, NNRTI- non-nucleoside reverse transcriptase inhibitor, PI- Protease Inhibitors

	Total n(%)	Positive (n=23)	Negative (n=141)	P value
ART regime				0.5
Naïve	3 (1.8)	0 (0)	3 (2.1)	
First-line [2 NRTI + 1 NNRTI]	156 (95.1)	23 (100)	133 (94.4)	
Second Line [2NRTI + 1PI]	5 (3.0)	0 (0)	5 (3.5)	
Drug				0.36
TLE	92 (56.1)	18(78.3)	74(52.5)	
TLN	3 (1.8)	1(4.3)	2(1.4)	
ZLN	53 (32.3)	4(17.4)	49(34.8)	
ZLE	7 (4.3)	0(0)	7(5.0)	
TLA/r	2 (1.2)	0(0)	2(1.4)	
ZLA/r	3 (1.8%)	0(0)	3(2.1)	